Cart
sales@molnova.com
Pascolizumab
CAS No. 331243-22-2
Pascolizumab( —— )
Catalog No. M36890 CAS No. 331243-22-2
Pascolizumab (SB-240683) is a humanized monoclonal antibody targeting IL-4, exhibiting asthmatic effects and useful for studying allergic rhinitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 560 | In Stock |
|
| 10MG | 911 | In Stock |
|
| 25MG | 1349 | In Stock |
|
| 50MG | 1786 | In Stock |
|
| 100MG | 2409 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePascolizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPascolizumab (SB-240683) is a humanized monoclonal antibody targeting IL-4, exhibiting asthmatic effects and useful for studying allergic rhinitis.
-
DescriptionPascolizumab (SB-240683) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for the research of asthma.
-
In VitroCell Proliferation Assay Cell Line:human or monkey T cells Concentration:0-10000 pM Incubation Time:3 days Result:Inhibited the response of human and monkey T cells to recombinant monkey IL-4 (2 ng/ml) with IC50 values of 268 pM and 587 pM, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number331243-22-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hart TK, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002 Oct;130(1):93-100.?
molnova catalog
related products
-
Deoxyandrographolide
Deoxyandrographolide potentiates NGF-induced neurite outgrowth. Deoxyandrographolide suppresses the production of proinflammatory mediators TNF-α and IL-6.
-
Ixekizumab
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.
-
Xeligekimab
Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.
